Sung‐Young Shin
YOU?
Author Swipe
View article: TSG6 promotes epithelial-mesenchymal transition and tumor-associated macrophage polarization through Smad2/3 and MAPK signaling by facilitating TSG6-CD44-TGFβR1 or EGFR complex formation
TSG6 promotes epithelial-mesenchymal transition and tumor-associated macrophage polarization through Smad2/3 and MAPK signaling by facilitating TSG6-CD44-TGFβR1 or EGFR complex formation Open
TSG6 is highly expressed during PLK1-induced epithelial-mesenchymal transition (EMT). However, the role of TSG6 in the tumor microenvironment (TME) remains poorly understood. We investigate the function and regulatory mechanisms of TSG6 in…
View article: Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancer
Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancer Open
The PEAK family of pseudokinases, comprising PEAK1-3, play oncogenic roles in several poor prognosis human cancers, including triple negative breast cancer (TNBC). However, therapeutic targeting of pseudokinases is challenging due to their…
View article: Ribosomal Biogenesis Hyperactivation and ErbB signalling Mediated Network Rewiring Causes Adaptive Resistance to FGFR2 Inhibition
Ribosomal Biogenesis Hyperactivation and ErbB signalling Mediated Network Rewiring Causes Adaptive Resistance to FGFR2 Inhibition Open
Fibroblast Growth Factor Receptor 2 inhibition presents a promising therapeutic approach for restraining the growth and survival of cancer cells, particularly in breast tumours. However, the emergence of resistance to FGFR2 inhibitors like…
View article: Supplementary Data from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers
Supplementary Data from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers Open
Supplementary Notes, Supplementary Figures, and Supplementary Figure Legends
View article: Supplementary Data S1 from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers
Supplementary Data S1 from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers Open
Supplementary Data S1 - SBML model file
View article: Supplementary Data S2 from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers
Supplementary Data S2 from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers Open
Supplementary Data S2
View article: Supplementary Data S5 from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers
Supplementary Data S5 from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers Open
Supplementary Data S5
View article: Supplementary Data S3 from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers
Supplementary Data S3 from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers Open
Supplementary Data S3
View article: Data from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers
Data from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers Open
Oncogenic FGFR4 signaling represents a potential therapeutic target in various cancer types, including triple-negative breast cancer and hepatocellular carcinoma. However, resistance to FGFR4 single-agent therapy remains a major challenge,…
View article: Supplementary Data S4 from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers
Supplementary Data S4 from Integrative Modeling of Signaling Network Dynamics Identifies Cell Type–Selective Therapeutic Strategies for FGFR4-Driven Cancers Open
Supplementary Data S4
View article: GeneSurv: Multi-Gene Cancer Survival Analysis Tool
GeneSurv: Multi-Gene Cancer Survival Analysis Tool Open
Summary Traditional cancer survival analysis tools often restrict their analysis to single genes, thereby limiting their analytical scope. GeneSurv, a novel Web-Based Multi-Gene Cancer Survival Analysis Tool, addresses this limitation by e…
View article: Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically ‘actionable’ signalling axis in triple negative breast cancer
Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically ‘actionable’ signalling axis in triple negative breast cancer Open
Summary The PEAK family of pseudokinases, comprising PEAK1-3, are signalling scaffolds that play oncogenic roles in several poor prognosis human cancers, including triple negative breast cancer (TNBC). However, therapeutic targeting of pse…
View article: Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer
Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer Open
Utility of PI3Kα inhibitors like BYL719 is limited by the acquisition of genetic and non-genetic mechanisms of resistance which cause disease recurrence. Several combination therapies based on PI3K inhibition have been proposed, but a way …
View article: Author Response: Systematic Analysis of Network-driven Adaptive Resistance to CDK4/6 and Estrogen Receptor Inhibition using Meta-Dynamic Network Modelling
Author Response: Systematic Analysis of Network-driven Adaptive Resistance to CDK4/6 and Estrogen Receptor Inhibition using Meta-Dynamic Network Modelling Open
Drug resistance inevitably emerges during the treatment of cancer by targeted therapy. Adaptive resistance is a major form of drug resistance, wherein the rewiring of protein signalling networks in response to drug perturbation allows the …
View article: Systematic Analysis of Network-driven Adaptive Resistance to CDK4/6 and Estrogen Receptor Inhibition using Meta-Dynamic Network Modelling
Systematic Analysis of Network-driven Adaptive Resistance to CDK4/6 and Estrogen Receptor Inhibition using Meta-Dynamic Network Modelling Open
Drug resistance inevitably emerges during the treatment of cancer by targeted therapy. Adaptive resistance is a major form of drug resistance, wherein the rewiring of protein signalling networks in response to drug perturbation allows the …
View article: Systematic Analysis of Network-driven Adaptive Resistance to CDK4/6 and Estrogen Receptor Inhibition using Meta-Dynamic Network Modelling
Systematic Analysis of Network-driven Adaptive Resistance to CDK4/6 and Estrogen Receptor Inhibition using Meta-Dynamic Network Modelling Open
Drug resistance inevitably emerges during the treatment of cancer by targeted therapy. Adaptive resistance is a major form of drug resistance, wherein the rewiring of protein signalling networks in response to drug perturbation allows the …
View article: Galvanic engineering of interior hotspots in 3D Au/Ag bimetallic SERS nanocavities for ultrasensitive and rapid recognition of phthalate esters
Galvanic engineering of interior hotspots in 3D Au/Ag bimetallic SERS nanocavities for ultrasensitive and rapid recognition of phthalate esters Open
The ecological and health risks of plasticizer accumulation have reached the global public agenda. For early screening of phthalate esters (PAEs), in the present study, we developed ultrasensitive and reliable bimetallic surface-enhanced R…
View article: SynDISCO: A Mechanistic Modeling-Based Framework for Predictive Prioritization of Synergistic Drug Combinations Directed at Cell Signaling Networks
SynDISCO: A Mechanistic Modeling-Based Framework for Predictive Prioritization of Synergistic Drug Combinations Directed at Cell Signaling Networks Open
The widespread development of resistance to cancer monotherapies has prompted the need to identify combinatorial treatment approaches that circumvent drug resistance and achieve more durable clinical benefit. However, given the vast space …
View article: Supplementary Figure Legends from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Supplementary Figure Legends from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis Open
Legends for supplementary figures
View article: Supplementary Figure S4 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Supplementary Figure S4 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis Open
Supplementary Figure 4. PYK2 interacts with HER3 in a kinase dependent manner and suppresses NDRG1-induced HER3 proteasomal degradation.
View article: Supplementary Figure S4 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Supplementary Figure S4 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis Open
Supplementary Figure 4. PYK2 interacts with HER3 in a kinase dependent manner and suppresses NDRG1-induced HER3 proteasomal degradation.
View article: Supplementary Material and Methods from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Supplementary Material and Methods from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis Open
Supplemental Material and Methods
View article: Supplementary Figure S1 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Supplementary Figure S1 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis Open
Supplementary Figure 1. Effects of EGFR antagonists, FAK or PYK2/FAK inhibition/depletion on basal-like TNBC growth either alone or in combination.
View article: Supplementary Figure S3 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Supplementary Figure S3 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis Open
Supplementary Figure 3. Combined inhibition of PYK2/FAK and EGFR enhances pro-apoptotic signals and reduces pro-survival signals.
View article: Supplementary Table S2 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Supplementary Table S2 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis Open
Supplementary Table 2. Web links to affymetrix array data
View article: Data from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Data from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis Open
Triple-negative breast cancer (TNBC) is a highly aggressive, heterogeneous disease with poor prognosis and no effective targeted therapies. EGFR is highly expressed in basal-like TNBC and is considered as a potential therapeutic target. Ho…
View article: Supplementary Figure S3 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Supplementary Figure S3 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis Open
Supplementary Figure 3. Combined inhibition of PYK2/FAK and EGFR enhances pro-apoptotic signals and reduces pro-survival signals.
View article: Supplementary Figure Legends from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Supplementary Figure Legends from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis Open
Legends for supplementary figures